¼¼°èÀÇ C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ½ÃÀå
C-Reactive Protein Testing
»óǰÄÚµå : 1542758
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 244 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ¼¼°è ½ÃÀåÀº 2030³â±îÁö 32¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù

2023³â 29¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ¼¼°è ½ÃÀåÀº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR) 1.8%·Î ¼ºÀåÇÏ¿© 2030³â¿¡´Â 32¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ½ÉÇ÷°ü ÁúȯÀÇ C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç´Â CAGR 2.6%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 9¾ï 5,530¸¸ ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¾Ï Áúȯ ºÐ¾ßÀÇ C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»çÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 2.1%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 8¾ï 4,410¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 1.7%·Î ¼ºÀå Àü¸Á

¹Ì±¹ÀÇ C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ½ÃÀåÀº 2023³â 8¾ï 4,410¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 1.7%ÀÇ ¼ºÀå·üÀ» º¸À̸ç 2030³â¿¡´Â 5¾ï 8,100¸¸ ´Þ·¯ ±Ô¸ð¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 1.7%¿Í 1.3%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 1.9%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è C-¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ ¿ä¾à

¿°ÁõÀ» ³Ñ¾î C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç´Â ¹Ì±¹¿¡ ¹«¾ùÀ» °¡Á®¿Ã °ÍÀΰ¡?

C ¹ÝÀÀ¼º ´Ü¹éÁú(CRP) °Ë»ç´Â ¿°Áõ¿¡ ¹ÝÀÀÇÏ¿© °£¿¡¼­ »ý¼ºµÇ´Â ´Ü¹éÁúÀÎ Ç÷Áß CRP ¼öÄ¡¸¦ ÃøÁ¤Çϱâ À§ÇØ °í¾ÈµÈ ³Î¸® »ç¿ëµÇ´Â Áø´Ü µµ±¸·Î, CRPÀÇ Á¸Àç´Â ±Þ¼º °¨¿°¿¡¼­ ¸¸¼º Áúȯ, ÀÚ°¡¸é¿ª Áúȯ¿¡ À̸£±â±îÁö ´Ù¾çÇÑ Áúº´°ú °ü·ÃÀÌ ÀÖ½À´Ï´Ù. ¼öÄ¡¸¦ ÃøÁ¤ÇÔÀ¸·Î½á ÀÇ·áÁøÀº ü³» ¿°Áõ ¿©ºÎ¸¦ Æò°¡Çϰí, ±× ½É°¢¼ºÀ» ÆÇ´ÜÇϰí, Ä¡·á È¿°ú¸¦ ¸ð´ÏÅ͸µÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ °Ë»ç´Â ÀϹÝÀûÀ¸·Î CRP »ó½ÂÀ» À¯¹ßÇÏ´Â ¼¼±Õ °¨¿°°ú ¹ÙÀÌ·¯½º °¨¿°À» ±¸º°ÇÏ°í ·ù¸¶Æ¼½º °üÀý¿°À̳ª Å©·Ðº´°ú °°Àº ¸¸¼º ¿°Áõ¼º ÁúȯÀÇ Ä¡·á ÁöħÀÌ µÉ ¼ö Àֱ⠶§¹®¿¡ ƯÈ÷ °¡Ä¡°¡ ³ô½À´Ï´Ù.

±â¼úÀÌ CRP °Ë»çÀÇ Á¤È®¼º°ú Á¢±Ù¼ºÀ» ¾î¶»°Ô Çâ»ó½Ã۰í Àִ°¡?

ÀÇ·á±â¼úÀÇ ¹ßÀüÀ¸·Î CRP °Ë»çÀÇ Á¤È®¼º°ú À¯¿ë¼ºÀÌ Å©°Ô Çâ»óµÇ¾ú½À´Ï´Ù. ÃֽŠCRP °Ë»ç´Â ¸î ºÐ ¾È¿¡ °á°ú¸¦ ¾òÀ» ¼ö ÀÖ¾î ½Å¼ÓÇÑ ÀÓ»óÀû ÆÇ´ÜÀ» °¡´ÉÇÏ°Ô ÇÕ´Ï´Ù. ƯÈ÷ ȯÀÚÀÇ Ä§´ë ¿·À̳ª Áø·á½Ç¿¡¼­ Á÷Á¢ »ç¿ëÇÒ ¼ö ÀÖ´Â ÇöÀå Áø·á¿ë CRP °Ë»ç Àåºñ´Â ƯÈ÷ ȹ±âÀûÀÔ´Ï´Ù. °Ë»ç½Ç·Î »ùÇÃÀ» º¸³¾ Çʿ䰡 ¾ø°í, °á°ú¸¦ ±â´Ù¸®´Â ½Ã°£µµ ´ÜÃàÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÃÖ±Ù ¸¶ÀÌÅ©·ÎÇ÷çÀ̵ñ½º°øÇÐ ¹× ¹ÙÀÌ¿À¼¾½Ì ±â¼úÀÇ ¹ßÀüÀº ÀûÀº ¾çÀÇ Ç÷¾× »ùÇÃÀ» ÇÊ¿ä·Î ÇÏ´Â ´õ ÀÛ°í ¹Î°¨ÇÑ CRP °Ë»ç ÀåºñÀÇ °³¹ß·Î À̾îÁö°í ÀÖ½À´Ï´Ù.

CRP °Ë»ç ½Ç½Ã¿¡ ¾î¶² ¹®Á¦°¡ Àִ°¡?

CRP °Ë»çÀÇ ÀåÁ¡¿¡µµ ºÒ±¸Çϰí, CRP °Ë»ç ½ÃÇà¿¡´Â ¸î °¡Áö ¹®Á¦°¡ ÀÖ½À´Ï´Ù. ÁÖ¿ä ¿ì·Á »çÇ× Áß Çϳª´Â CRP °ªÀÌ È®Á¤ÀûÀÎ Áø´Ü Á¤º¸¸¦ Á¦°øÇÏÁö ¾Ê´Â »óȲ¿¡¼­ CRP °Ë»ç°¡ °úµµÇÏ°Ô »ç¿ëµÇ°Å³ª ¿À¿ëµÉ ¼ö ÀÖÀ¸¸ç, CRP °á°ú¸¦ À߸ø ÇØ¼®ÇÏ¸é ¹ÙÀÌ·¯½º °¨¿°¿¡ ´ëÇÑ ºÎÀûÀýÇÑ Ç×»ýÁ¦ »ç¿ë°ú °°Àº ºÒÇÊ¿äÇÑ Ä¡·á·Î À̾îÁú ¼ö ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå Áø·á CRP °Ë»ç´Â Æí¸®ÇÔÀ» Á¦°øÇÏÁö¸¸, ¸ðµç ÀÇ·á ÇöÀå¿¡¼­ CRP °Ë»çÀÇ Á¤È®¼º°ú ½Å·Ú¼ºÀ» º¸ÀåÇÏ´Â °ÍÀÌ Áß¿äÇÏÁö¸¸, CRP °Ë»çÀÇ ÀåÁ¡À» ±Ø´ëÈ­Çϰí ÀáÀçÀûÀÎ ´ÜÁ¡À» ÇÇÇϱâ À§Çؼ­´Â CRP °Ë»ç °á°ú¸¦ ÀÌÇØÇϰí ÀÓ»ó ÇöÀå¿¡ È¿°úÀûÀ¸·Î ÅëÇÕÇÒ ¼ö ÀÖ´Â ÀÇ·áÁøµéÀÇ ÀνÄÀÌ ÇÊ¿äÇÕ´Ï´Ù. ÀÓ»ó ÇöÀå¿¡¼­ CRP °Ë»ç °á°ú¸¦ ÀÌÇØÇϰí È¿°úÀûÀ¸·Î ÅëÇÕÇÒ ¼ö ÀÖµµ·Ï ÀÇ·áÁøÀ» ±³À°ÇÏ´Â °ÍÀÌ ÇʼöÀûÀÔ´Ï´Ù.

CRP °Ë»ç ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?

C ¹ÝÀÀ¼º ´Ü¹éÁú °Ë»ç ½ÃÀåÀÇ ¼ºÀåÀº ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ½ÉÇ÷°ü Áúȯ, ·ù¸¶Æ¼½º °üÀý¿°, ¿°Áõ¼º Àå Áúȯ°ú °°Àº ¿°Áõ¼º ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó CRP °Ë»ç¿Í °°Àº È¿°úÀûÀÎ Áø´Ü ¹× ¸ð´ÏÅ͸µ µµ±¸¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¿°ÁõÀÇ Á߿伺°ú ´Ù¾çÇÑ °Ç°­ »óÅ¿¡¼­ÀÇ ¿°ÁõÀÇ ¿ªÇÒ¿¡ ´ëÇÑ ÀÇ»ç¿Í ȯÀÚÀÇ ÀνÄÀÌ ³ô¾ÆÁø °Íµµ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÇöÀå Áø´ÜÀÇ È®´ë¿Í Àú·ÅÇÑ °¡°ÝÀÇ ½Å¼ÓÇÑ CRP °Ë»ç ÀåºñÀÇ º¸±ÞÀÌ È®´ëµÊ¿¡ µû¶ó º¸´Ù ¸¹Àº »ç¶÷µéÀÌ CRP °Ë»ç¸¦ ½±°Ô ÀÌ¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù. ÀÇ·á ½Ã½ºÅÛÀÌ ¿¹¹æ°ú Á¶±â °³ÀÔÀ» Áß½ÃÇÏ´Â °¡¿îµ¥, CRP °Ë»ç´Â ÀÇ·áÀÇ ¼ÒÁßÇÑ ¹«±â·Î ÀÚ¸®¸Å±èÇÏ¸ç ´Ù¾çÇÑ ÀÇ·á ȯ°æ¿¡¼­ äÅðú ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñ¹Þ´Â 43°³ ±â¾÷)

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings(LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    • ½ÃÀå °³¿ä
    • ÁÖ¿ä ±â¾÷
    • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
    • ¼¼°è ½ÃÀå Àü¸Á

    Á¦3Àå ½ÃÀå ºÐ¼®

    • ¹Ì±¹
    • ij³ª´Ù
    • ÀϺ»
    • Áß±¹
    • À¯·´
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ±âŸ Áö¿ª

    Á¦4Àå °æÀï

    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Global C-Reactive Protein Testing Market to Reach US$3.2 Billion by 2030

    The global market for C-Reactive Protein Testing estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. C-Reactive Protein Testing for Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$955.3 Million by the end of the analysis period. Growth in the C-Reactive Protein Testing for Cancer Disease segment is estimated at 2.1% CAGR over the analysis period.

    The U.S. Market is Estimated at US$844.1 Million While China is Forecast to Grow at 1.7% CAGR

    The C-Reactive Protein Testing market in the U.S. is estimated at US$844.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$581.0 Million by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

    Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

    Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

    C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn's disease.

    How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

    The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor's office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

    What Challenges Are Faced in the Implementation of CRP Testing?

    Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test's benefits and avoid potential drawbacks.

    What Key Factors Are Fueling the Expansion of the CRP Testing Market?

    The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

    Select Competitors (Total 43 Featured) -

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    III. MARKET ANALYSIS

    IV. COMPETITION

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â